<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-08-26T13:36:10Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/27171203-C85A-44A9-98E5-A0326EB40E1B" ns1:id="27171203-C85A-44A9-98E5-A0326EB40E1B"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/9BC3F420-DF47-4E04-A2E2-EC437A3C8D1E" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/9BC3F420-DF47-4E04-A2E2-EC437A3C8D1E" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/53F8943B-9908-4B04-90F8-64BBA456CBCC" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/FAABF2EB-AEB2-4A67-A79E-39B8F8121932" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2009-05-30T23:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/D240D57B-4DFB-482B-849A-A3FE1B3FBFB6" ns1:rel="FUND" ns1:start="2006-12-01T00:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">100048</ns2:identifier></ns2:identifiers><ns2:title>regenative Stants to treat cardiovas. Disease.</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>Collaborative R&amp;D</ns2:grantCategory><ns2:leadFunder>Innovate UK</ns2:leadFunder><ns2:abstractText>Cardiovascular disease (CVD) is the most serious health concern facing the UK. Stents have been one of the most important advances in the treatment of CVD, but restenosis (inflammatory thickening of artery caused by the stent) and late thrombosis are major problems. This project will provide crucial platform technologies and develop a new benchmark in stent technology. Applied science research will create a surface-modified stent with a bioactive cellular scaffold coat - a novel regenerative implant that promotes vascular repair. Stem cell-derived, non- GM, endovascular cells that provide a localised immune privileged site and controlled vascular repair combined with a programmable polymer coronary stent surface coating will give a targeted delivery system. Industry ready platform technologies will be developed that can also support other cell-based regenerative therapeutics, cell delivery systems, scaffolds, in vivo modelling and GMP production.</ns2:abstractText></ns2:project>